Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cost of Revenue (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Cost of Revenue for 13 consecutive years, with $479000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $479000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 5.45% decrease, with the full-year FY2024 number at $3.3 million, down 24.5% from a year prior.
  • Cost of Revenue was $479000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $1.4 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.1 million in Q4 2022 to a low of -$2.3 million in Q4 2021.
  • A 5-year average of $1.0 million and a median of $1.0 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 174.7% in 2021, then skyrocketed 336.26% in 2022.
  • NovaBay Pharmaceuticals' Cost of Revenue stood at -$2.3 million in 2021, then soared by 235.95% to $3.1 million in 2022, then tumbled by 66.76% to $1.0 million in 2023, then skyrocketed by 41.16% to $1.4 million in 2024, then plummeted by 66.67% to $479000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Cost of Revenue are $479000.0 (Q3 2025), $1.4 million (Q4 2024), and $808000.0 (Q2 2024).